Pure Global
NCT06118762

Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer

A Single-arm, Open, Multicenter Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer
The First Affiliated Hospital of Nanchang University·Phase 4·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Metastatic Colorectal Cancer
Drug/Device/Intervention
Fruquintinib
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
The First Affiliated Hospital of Nanchang University
Location
Nanchang, China
Timeline & enrollment
Phase
Phase 4
Start date
Oct 20, 2023
End date
Oct 01, 2026
Enrollment
30 participants
Primary outcome

Progression free survival (PFS)

Summary

To evaluate the efficacy and safety of Fruquintinib combined with Raltitrexed in the
 treatment of metastatic colorectal cancer that progressed or could not be tolerated after
 previous fluorouracil, oxaliplatin, and irinotecan based therapy

ICD-10 classifications
Malignant neoplasm of colonMalignant neoplasm: Colon, unspecifiedMalignant neoplasm: Descending colonMalignant neoplasm: Ascending colonMalignant neoplasm: Overlapping lesion of colon
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06118762
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06118762 through Pure Global AI's free database. This Phase 4 trial is sponsored by The First Affiliated Hospital of Nanchang University and is currently Recruiting. The study focuses on Metastatic Colorectal Cancer. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.